John Klim, DO
Pain Medicine · Noblesville, INNPI 1508834672
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,615 of the $7,538 with a category attached, or 61.2%. It is spread thinly across 34 manufacturers, the largest accounting for just 18.4%. Reporting peaked in 2024 at $2,740 and has fallen 76.2% since, to $652 in 2025.
Across 173 payments — averaging $43.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Si-bone, Inc.$1K
- Relievant Medsystems, Inc.$1K
- Curonix LLC$947
- Boston Scientific$587
- Collegium Pharmaceutical, Inc.$550
- Averitas Pharma Inc.$282
- plus $2K from 28 others
What the payments were for
- Travel & lodging$2,92339%
- Food & beverage$4,61561%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Si-bone, Inc. | 9 | $1,389 |
| Relievant Medsystems, Inc. | 8 | $1,373 |
| Curonix LLC | 9 | $947 |
| Boston Scientific | 8 | $587 |
| Collegium Pharmaceutical, Inc. | 33 | $550 |
| Averitas Pharma Inc. | 13 | $282 |
| GRT US Holding, Inc. | 16 | $279 |
| Abbott | 10 | $272 |
| Arbor Pharmaceuticals, Inc. | 3 | $250 |
| Medtronic | 9 | $199 |
| SPR Therapeutics, Inc | 2 | $150 |
| Nevro Corp. | 1 | $148 |
| Globus Medical | 5 | $135 |
| Pfizer | 7 | $113 |
| Johnson & Johnson | 5 | $105 |
| Redhill Biopharma Inc. | 5 | $90 |
| Amgen | 4 | $77 |
| Spinal Simplicity, LLC | 1 | $67 |
| Vertex | 2 | $56 |
| AbbVie | 3 | $54 |
| Indivior Inc. | 4 | $53 |
| Bioventus LLC | 2 | $48 |
| Stryker | 1 | $45 |
| Painteq LLC | 1 | $38 |
| Valinor Pharma, LLC | 2 | $37 |
| Lundbeck LLC | 1 | $32 |
| Orexo US, Inc. | 2 | $32 |
| Scilex Pharmaceuticals Inc. | 1 | $21 |
| Tonix Medicines, Inc. | 1 | $21 |
| Angiodynamics, Inc. | 1 | $20 |
| Saluda Medical Americas, Inc. | 1 | $17 |
| Medline Industries LP | 1 | $17 |
| MML US, Inc. | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,538 in reported general payments places this provider in the 70th percentile of 128 pain medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 17 | $15,298 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 529 | $12,211 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 360 | $10,023 |
| Buprenorphine | 30 | $9,921 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 60 | $4,751 |
| Naloxone Hcl | 92 | $4,154 |
| Pregabalin | 55 | $2,169 |
| Oxycodone Hcl | 86 | $1,126 |
| Lidocaine | 13 | $1,116 |
| Morphine Sulfate ErMorphine Sulfate | 44 | $945 |
| Tizanidine Hcl | 33 | $831 |
| Gabapentin | 70 | $780 |
| Methocarbamol | 24 | $432 |
| Meloxicam | 24 | $431 |
| Hydromorphone Hcl | 39 | $398 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er | $550 | $15,29817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 128 pain medicine providers in Indiana.
Other pain medicine in Noblesville
- Derron WilsonCarmel$616K
- Kevin MacadaegCarmel$337K
- Andrew TrobridgeMuncie$253K
- Meredith LanghorstFishers$233K
- Abhishek DasMishawaka$186K
- Rajiv TewariFishers$140K
- John SwoffordIndianapolis$127K
- Neal ColemanMuncie$38K
- Matthew DevriesLafayette$37K
- Amer KaziGranger$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.